Obestatin

Overview

Obestatin is a 23-amino acid C-terminally amidated peptide encoded within the same preproghrelin (GHRL) gene as ghrelin. It was identified in 2005 by Aaron Hsueh's laboratory at Stanford through a bioinformatic search for conserved C-terminal amidation motifs within known prohormone sequences. The discovery team reported that obestatin suppressed food intake, reduced body weight gain, and acted through the orphan GPCR GPR39 — a receptor previously implicated in zinc sensing and gastrointestinal function.

The original report attracted substantial attention because it suggested that a single gene could produce two peptides with opposite effects on food intake: ghrelin (orexigenic) and obestatin (anorexigenic). Analogous "yin-yang" peptide pairs are uncommon in endocrinology and would have offered an elegant mechanism for bidirectional appetite regulation.

However, subsequent attempts by multiple independent laboratories to replicate the original findings produced mixed and often negative results. Many groups failed to reproduce obestatin's feeding suppression, its binding to GPR39, or its proposed physiological roles. A 2008 retraction or partial retraction affected some aspects of the original claims. Later work has found more modest or context-dependent effects of obestatin on gastrointestinal motility, pancreatic function, cell proliferation, and other processes, though the core feeding-suppressant claim and GPR39 receptor identification remain disputed.

Obestatin nevertheless remains a valid research peptide, and it serves as a widely cited case study in peptide biology regarding replication, orphan receptor deorphanization, and the complexity of prohormone processing. This article describes the peptide's chemistry and the research literature while acknowledging the unresolved scientific status of key physiological claims.

Structure/Sequence

Human Obestatin: FNAPFDVGIKLSGVQYQQHSQAL-NH₂ (23 aa, C-terminal amidation)

• Length: 23 amino acids
• Molecular weight: ~2,547 g/mol
• Gene: GHRL (chromosome 3p26-p25; same gene as ghrelin)
• Location in prepropeptide: Residues 76-98 of preproghrelin (after signal peptide cleavage)
• C-terminal amidation: Required for proposed biological activity
• No acylation: Unlike ghrelin, obestatin is not octanoylated

Relationship to Ghrelin

The preproghrelin precursor (117 aa) is processed to:

• Ghrelin (residues 24-51): 28-aa octanoylated orexigenic peptide
• Obestatin (residues 76-98): 23-aa C-terminally amidated peptide
• Intermediate sequences: Non-bioactive spacer regions

The two peptides share a gene but not a sequence similarity — they are distinct proteolytic products that happen to originate from the same open reading frame.

Conservation

Obestatin is conserved across mammals, with moderate sequence variation. C-terminal amidation is conserved.

Mechanism of Action

GPR39 (Disputed)

The original 2005 report proposed GPR39 as the obestatin receptor. Subsequent studies have:

• Failed to reproduce obestatin binding to GPR39 in most assay systems
• Confirmed that GPR39 is a zinc-sensing receptor with established ligand-receptor pharmacology
• Found obestatin effects in GPR39-null animals, suggesting alternative receptors
• The identity of obestatin's receptor remains unclear

Proposed Effects (Mixed Replication)

Originally reported:

• Suppression of food intake
• Reduced body weight gain
• Reduced gastric emptying
• Opposition to ghrelin orexigenic effects

Subsequent findings with mixed support:

• Gastrointestinal motility modulation (some studies positive, others negative)
• Pancreatic β-cell effects on insulin and glucose-stimulated insulin secretion
• Proliferative effects on various cell lines (myocytes, adipocytes, β-cells)
• Effects on sleep-wake behavior
• Cardiovascular effects

Mechanisms Reported Downstream

When effects are observed, various signaling pathways have been implicated:

• cAMP elevation (disputed)
• ERK activation
• PI3K/Akt pathway
• Effects on apoptosis and proliferation in cell culture

Circulating Levels

Obestatin is detectable in plasma by some assays:

• Ghrelin:obestatin ratio has been proposed as a biomarker
• Circulating obestatin fluctuates with feeding state in some studies
• Levels altered in metabolic disease — direction of change is assay-dependent and inconsistent across studies

Research Summary

Common Discussion Topics

1. Replication controversy — Obestatin is one of the most widely cited examples in modern peptide research of a promising initial finding that did not robustly replicate across laboratories. This has made it a teaching case for the importance of independent replication before establishing new physiological axes.

2. GPR39 disputed status — The proposed obestatin-GPR39 pharmacology has largely not been supported by later work. GPR39 is now better characterized as a zinc-sensing GPCR. This illustrates the challenges of orphan receptor deorphanization.

3. One gene, two peptides — The dual-peptide architecture of preproghrelin (producing both ghrelin and obestatin) is biochemically established even if obestatin's function is disputed. Other examples of dual-peptide prohormones include POMC (producing β-endorphin, ACTH, α-MSH) and preprosomatostatin (somatostatin-14 and -28).

4. Context-dependent effects — Even when individual obestatin effects are not robustly reproducible, patterns emerge suggesting genuine activity on GI motility, β-cell biology, and cell proliferation in specific contexts. The lack of a clear receptor complicates interpretation.

5. Commercial vs research reality — Despite the scientific controversies, obestatin has circulated in commercial and supplement contexts. The gap between scientific uncertainty and commercial claims illustrates the broader challenges of peptide research translation.

Related Compounds

• Ghrelin — same-gene counterpart with opposite (orexigenic) effect
• Motilin — related gut peptide with motility-regulating activity
• Cholecystokinin — established satiety peptide